|
Objective: To evalue the effectiveness and safety of cyclosporin A treatment for idiopathic membranous nephropathy by meta analysis.Methods:In the Cochrane Library, Medline, Embase, Science Citation Index (SCI), Biological Abstracts (BA), OVID, ASP, VIP and CNKI-China Academic Journal (1980-2011 years) before the retrieved 2011-03-20 published randomized controlled trials. By two authors independently extracted data, the methodological quality of included studies with Jadad quality score, using the Cochrane Collaboration to provide special RevMan5.0.14 statistical analysis software.Results:4 trials involving 114 patients were inclued in the meta-analysis. Meta analysis showed: (1) cyclosporine A treatment for idiopathic membranous nephropathy can increase the overall response rate of proteinuria (OR = 3.59,95% CI 1.41 ~ 9.15, p <0.05) and complete remission rate ( OR = 3.65,95% CI 1.05 ~ 12.76, p <0.05), but the partial response rate (OR = 1.79,95% CI 0.7 ~ 4.58, p > 0.05) and recurrence rate (OR = 1.07,95% CI 0.05 ~ 21.00, p > 0.05) was no difference. (2) cyclosporine A group compared with the control group, can delay the progress of renal dysfunction (OR = 21.86,95% CI 5.75 ~ 37.98, p <0.05), but failed to mitigate the level of serum albumin (OR = 7.14, 95% CI -6.58 ~ 20.86, p > 0.05). (3) cyclosporine A more likely cause gastrointestinal symptoms (OR = 4.3,95% CI 1.01 ~ 18.38, p = 0.05), while in other side effects,such as hypertensive there was no significant difference ( OR = 1.43,95% CI 0.54 ~ 3. 77, p > 0.05). Conclusion : Cyclosporin A treatment for idiopathic membranous nephropathy can increase the overall response rate and complete remission rate of proteinuria, can delay the progress of renal dysfunction, more likely cause gastrointestinal symptoms.
|